Header Logo

Connection

KENNETH MCCLAIN to Humans

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Humans.
KENNETH MCCLAIN
Connection Strength
0.828
Humans
  1. Mixed histiocytic disorders: Nature versus nurture? Br J Haematol. 2024 Jul; 205(1):20-21.
    View in: PubMed
    Score: 0.023
  2. Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol. 2023; 40(5):497-505.
    View in: PubMed
    Score: 0.021
  3. BRAF V600E vs cell of origin: what governs LCH? Blood. 2021 10 07; 138(14):1203-1204.
    View in: PubMed
    Score: 0.019
  4. Histiocytic disorders. Nat Rev Dis Primers. 2021 10 07; 7(1):73.
    View in: PubMed
    Score: 0.019
  5. Histiocytic Diseases of Neonates: Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Juvenile Xanthogranuloma. Clin Perinatol. 2021 03; 48(1):167-179.
    View in: PubMed
    Score: 0.018
  6. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.018
  7. ALPS or not? Blood. 2020 10 22; 136(17):1895-1896.
    View in: PubMed
    Score: 0.018
  8. Treatment of hemophagocytic lymphohistiocytosis in the era of new biologics. Pediatr Blood Cancer. 2020 10; 67(10):e28631.
    View in: PubMed
    Score: 0.017
  9. Management of severe pulmonary Langerhans cell histiocytosis in children. Pediatr Pulmonol. 2020 08; 55(8):2074-2081.
    View in: PubMed
    Score: 0.017
  10. Checkmate for EBV-HLH. Blood. 2020 03 12; 135(11):782-784.
    View in: PubMed
    Score: 0.017
  11. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
    View in: PubMed
    Score: 0.016
  12. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.016
  13. Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
    View in: PubMed
    Score: 0.016
  14. HLH: watch and wait, or act and cure? Blood. 2018 11 08; 132(19):2005-2006.
    View in: PubMed
    Score: 0.015
  15. Langerhans-Cell Histiocytosis. N Engl J Med. 2018 08 30; 379(9):856-868.
    View in: PubMed
    Score: 0.015
  16. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.015
  17. Fire behind the fury: IL-18 and MAS. Blood. 2018 03 29; 131(13):1393-1394.
    View in: PubMed
    Score: 0.015
  18. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. J Pediatr. 2017 10; 189:72-78.e3.
    View in: PubMed
    Score: 0.014
  19. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.013
  20. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.012
  21. Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo. Br J Haematol. 2015 Oct; 171(1):150-1.
    View in: PubMed
    Score: 0.012
  22. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015; 2015:177-82.
    View in: PubMed
    Score: 0.012
  23. fHLH: becoming a blended family. Blood. 2014 Aug 21; 124(8):1210-1.
    View in: PubMed
    Score: 0.012
  24. Why do T cells cause so much trouble? Blood. 2014 Mar 27; 123(13):1978.
    View in: PubMed
    Score: 0.011
  25. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14; 8:72.
    View in: PubMed
    Score: 0.011
  26. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.010
  27. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011 Oct 13; 118(15):4041-52.
    View in: PubMed
    Score: 0.009
  28. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011 Jan; 56(1):154-5.
    View in: PubMed
    Score: 0.009
  29. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.009
  30. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.008
  31. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer. 2010 Mar; 54(3):424-8.
    View in: PubMed
    Score: 0.008
  32. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5.
    View in: PubMed
    Score: 0.008
  33. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med. 2009 May; 15(5):483-4; author reply 484-5.
    View in: PubMed
    Score: 0.008
  34. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.008
  35. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.008
  36. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Jun; 50(6):1227-35.
    View in: PubMed
    Score: 0.008
  37. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer. 2008 Mar; 50(3):728-30.
    View in: PubMed
    Score: 0.007
  38. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today (Barc). 2007 Sep; 43(9):627-43.
    View in: PubMed
    Score: 0.007
  39. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.007
  40. Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 Jul 28; 10(14):5087-5096.
    View in: PubMed
    Score: 0.007
  41. Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas). Blood. 2026 07 16; 148(3):275-288.
    View in: PubMed
    Score: 0.007
  42. Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 Jul 14; 10(13):4776-4785.
    View in: PubMed
    Score: 0.007
  43. Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells. Blood Adv. 2026 Apr 28; 10(8):2711-2726.
    View in: PubMed
    Score: 0.007
  44. Lenalidomide-Dexamethasone as an Effective and?Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and?Pharmacophenomic Study. Am J Hematol. 2026 Jul; 101(7):1478-1483.
    View in: PubMed
    Score: 0.006
  45. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005 Nov; 6(14):2435-41.
    View in: PubMed
    Score: 0.006
  46. Intracranial plasma cell granuloma: case report and treatment of recurrence with methotrexate and 6-mercaptopurine. J Pediatr Hematol Oncol. 2005 Nov; 27(11):599-603.
    View in: PubMed
    Score: 0.006
  47. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 07 10; 146(2):206-218.
    View in: PubMed
    Score: 0.006
  48. Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder. J Clin Endocrinol Metab. 2025 May 19; 110(6):1756-1766.
    View in: PubMed
    Score: 0.006
  49. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.
    View in: PubMed
    Score: 0.006
  50. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.006
  51. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.006
  52. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004; 283-96.
    View in: PubMed
    Score: 0.006
  53. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 12 12; 56(12):2790-2802.e6.
    View in: PubMed
    Score: 0.006
  54. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.006
  55. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
    View in: PubMed
    Score: 0.005
  56. Patient-reported fatigue and pain in Erdheim-Chester disease: a registry-based, mixed methods study. Haematologica. 2023 06 01; 108(6):1685-1690.
    View in: PubMed
    Score: 0.005
  57. Hemophagocytic lymphohistiocytosis masquerading as child abuse: presentation of three cases and review of central nervous system findings in hemophagocytic lymphohistiocytosis. Pediatrics. 2003 May; 111(5 Pt 1):e636-40.
    View in: PubMed
    Score: 0.005
  58. Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS. AJNR Am J Neuroradiol. 2022 11; 43(11):1667-1673.
    View in: PubMed
    Score: 0.005
  59. Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol. 2002 Jul; 39(1):35-9.
    View in: PubMed
    Score: 0.005
  60. Clinical and molecular features of pediatric cancer patients with Lynch syndrome. Pediatr Blood Cancer. 2022 11; 69(11):e29859.
    View in: PubMed
    Score: 0.005
  61. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.005
  62. IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467.
    View in: PubMed
    Score: 0.005
  63. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.005
  64. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
    View in: PubMed
    Score: 0.005
  65. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
    View in: PubMed
    Score: 0.005
  66. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol. 2021 02; 192(3):667-671.
    View in: PubMed
    Score: 0.004
  67. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Adv. 2020 08 11; 4(15):3754-3766.
    View in: PubMed
    Score: 0.004
  68. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
    View in: PubMed
    Score: 0.004
  69. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
    View in: PubMed
    Score: 0.004
  70. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.004
  71. A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. Pediatr Blood Cancer. 2019 08; 66(8):e27798.
    View in: PubMed
    Score: 0.004
  72. Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis. Pediatr Crit Care Med. 2018 10; 19(10):e522-e530.
    View in: PubMed
    Score: 0.004
  73. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018 06 28; 131(26):2877-2890.
    View in: PubMed
    Score: 0.004
  74. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.004
  75. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.004
  76. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol. 1998 Mar; 30(3):175-7.
    View in: PubMed
    Score: 0.004
  77. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.004
  78. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018 Jan; 65(1).
    View in: PubMed
    Score: 0.004
  79. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 12 21; 130(25):2728-2738.
    View in: PubMed
    Score: 0.004
  80. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
    View in: PubMed
    Score: 0.004
  81. PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT. Clin Nucl Med. 2017 Aug; 42(8):582-588.
    View in: PubMed
    Score: 0.004
  82. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
    View in: PubMed
    Score: 0.004
  83. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
    View in: PubMed
    Score: 0.004
  84. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.003
  85. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.003
  86. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.003
  87. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.003
  88. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.003
  89. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015 Oct; 29(5):825-38.
    View in: PubMed
    Score: 0.003
  90. A 2-year-old with 4 weeks of daily fever. Pediatrics. 2015 May; 135(5):902-8.
    View in: PubMed
    Score: 0.003
  91. Recognition and treatment of concurrent active and neurodegenerative langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol. 2015 Jan; 37(1):e37-40.
    View in: PubMed
    Score: 0.003
  92. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. Br J Haematol. 2015 Apr; 169(2):241-8.
    View in: PubMed
    Score: 0.003
  93. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr; 169(2):299-301.
    View in: PubMed
    Score: 0.003
  94. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015 Jan 22; 125(4):591-9.
    View in: PubMed
    Score: 0.003
  95. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.003
  96. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
    View in: PubMed
    Score: 0.003
  97. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014; 7(9):6225-30.
    View in: PubMed
    Score: 0.003
  98. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014 Jul 24; 124(4):483-92.
    View in: PubMed
    Score: 0.003
  99. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014 Nov; 61(11):2101-3.
    View in: PubMed
    Score: 0.003
  100. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.003
  101. Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol. 2014 Apr; 31(3):253-7.
    View in: PubMed
    Score: 0.003
  102. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.003
  103. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62.
    View in: PubMed
    Score: 0.003
  104. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20; 121(25):5006-14.
    View in: PubMed
    Score: 0.003
  105. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.002
  106. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013 Jan; 60(1):101-9.
    View in: PubMed
    Score: 0.002
  107. Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther. 2011 Aug; 19(8):1433-9.
    View in: PubMed
    Score: 0.002
  108. Infection-associated hemophagocytic syndrome. Evidence for Epstein-Barr virus gene expression. Am J Pediatr Hematol Oncol. 1991; 13(4):476-81.
    View in: PubMed
    Score: 0.002
  109. Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Apr; 56(4):658-60.
    View in: PubMed
    Score: 0.002
  110. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010 Jun; 156(6):873-881.e1.
    View in: PubMed
    Score: 0.002
  111. Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease. Am J Surg Pathol. 2010 Apr; 34(4):589-94.
    View in: PubMed
    Score: 0.002
  112. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S82-9.
    View in: PubMed
    Score: 0.002
  113. Hemophagocytic lymphohistiocytosis in a patient with x-linked lymphoproliferative disease. Allergy Asthma Proc. 2009 Jul-Aug; 30(4):458-62.
    View in: PubMed
    Score: 0.002
  114. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009 May; 52(5):555-6.
    View in: PubMed
    Score: 0.002
  115. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008 Nov; 153(5):700-5, 705.e1-2.
    View in: PubMed
    Score: 0.002
  116. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep; 48(9):1971-80.
    View in: PubMed
    Score: 0.002
  117. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008 Feb; 50(2):381-3.
    View in: PubMed
    Score: 0.002
  118. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb; 48(2):124-31.
    View in: PubMed
    Score: 0.002
  119. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar; 44(3):251-4.
    View in: PubMed
    Score: 0.002
  120. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 01; 174(5):3067-71.
    View in: PubMed
    Score: 0.002
  121. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
    View in: PubMed
    Score: 0.001
  122. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May; 42(5):438-44.
    View in: PubMed
    Score: 0.001
  123. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J. 2003 Jul; 22(7):663-6.
    View in: PubMed
    Score: 0.001
  124. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003 May 14; 289(18):2393-9.
    View in: PubMed
    Score: 0.001
  125. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003 Feb 01; 36(3):306-12.
    View in: PubMed
    Score: 0.001
  126. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.001
  127. Human herpesvirus 6 and cytomegalovirus infections in children with human immunodeficiency virus infection and cancer. Pediatr Infect Dis J. 2002 Feb; 21(2):125-32.
    View in: PubMed
    Score: 0.001
  128. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
    View in: PubMed
    Score: 0.001
  129. Hodgkin's disease associated with central pontine myelinolysis. Med Pediatr Oncol. 1993; 21(4):311-4.
    View in: PubMed
    Score: 0.001
  130. Acquired immune deficiency, myelodysplasia, and acute nonlymphocytic leukemia associated with monosomy 7 and t(3;3) (q21;q26) in a child with Langerhans cell histiocytosis. Am J Pediatr Hematol Oncol. 1989; 11(2):153-7.
    View in: PubMed
    Score: 0.000
  131. Successful outcome of severe aplastic anemia following Epstein-Barr virus infection. Am J Hematol. 1988 Aug; 28(4):273-5.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.